Bharat Biotech’s Covaxin caused hospitalisation during early trials due to ‘adverse reaction’

Bharat Biotech is developing Covaxin in collaboration with ICMR - National Institute of Virology (NIV) and in its Phase III, it is conducting its largest clinical trial of a Covid-vaccine in India with 26,000 volunteers in 25 centres.

from The Financial Express https://ift.tt/3lOJdi6
https://ift.tt/eA8V8J FE Online